Construction and functional verification of AP-2 gene family eukaryotic expression vector

doi:10.16352/j.issn.1001-6325.2022.12.1829

Abstract

Abstract: Objective To construct the eukaryotic expression recombinant plasmids of activator protein 2(AP-2) family genes and to identify the effect of AP-2α, AP-2β and AP-2γ on proliferation and migration of HepG2 cell line. Methods Ap-2α,AP-2β and AP-2γ gene were amplified with human mammary cDNA library as template and ligated with pCDNA3.0-FLAG vector, respectively. The eukaryotic expression vector pCDNA3.0-FLAG-AP-2α/β/γ was constructed and transfected into HepG2 cells. CCK8 assay and clone formation assay were used to detect the effect of AP-2 family genes on HepG2 cell proliferation. Scratch assay was used to detect the effect of AP-2 family genes on HepG2 cell migration. Results The pCDNA3.0-FLAG-AP-2α/β/γ were successfully constructed and expressed in HepG2 cells.AP-2 family genes significantly inhibited the proliferation and migration of HepG2 cells(P＜0.05). Conclusions Ap-2α, AP-2β and AP-2γ may inhibit the proliferation and migration of HepG2 cells.

Key words: human AP-2 family genes, hepatocellular carcinoma, eukaryotic expression, cell line HepG2

CLC Number:

R735.7

MI Yue, JIANG Qi-wei, SHEN Yan-jie, ZHANG De-yu, YE Qi-nong. Construction and functional verification of AP-2 gene family eukaryotic expression vector[J]. Basic & Clinical Medicine, 2022, 42(12): 1829-1834.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2022.12.1829

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2022/V42/I12/1829

References

[1]Wiseman M. The second world cancer research fund/American institute for cancer research expert report. Food, nutrition, physical activity, and the prevention of cancer: A global perspective[J]. Proc Nutr Soc, 2008, 67: 253-256.
[2]Parkin DM, Pisani P, Ferlay J. Global cancer statistics[J]. CA Cancer J Clin, 1999, 49: 33-64.
[3]Eckert D, Buhl S, Weber S, et al. The AP-2 family of transcription factors[J]. Genome Biol, 2005, 6: 246. doi:10.1186/gb-2005-6-13-246.
[4]梁硕,邓红.转录因子AP-2在肿瘤发生中的双向调节作用[J]. 浙江大学学报(医学版), 2010, 39: 430-435.
[5]Huang W, Chen C, Liang Z, et al. AP-2α inhibits hepatocellular carcinoma cell growth and migration[J]. Int J Oncol, 2016, 48: 1125-1134.
[6]Lu Z, Xiao Z, Yang Z, et al. Hepatitis B virus X protein promotes human hepatoma cell growth via upregulation of transcription factor AP2α and sphingosine kinase 1[J]. Acta Pharmacol Sin, 2015, 36: 1228-1236.
[7]黄前川, 曹军皓, 季蒙. 癌基因DEK和转录因子AP-2α协同促进乳腺癌中HER2的高表达[J]. 基础医学与临床, 2010, 30: 175-178.
[8]Raap M, Gierendt L, Kreipe H, et al. Transcription factor AP-2beta in development, differentiation and tumorigenesis[J]. Int J Cancer, 2021, 149: 1221-1227.
[9]Yang L, Qiu J, Xiao Y, et al. AP-2β inhibits hepatocellular carcinoma invasion and metastasis through Slug and Snail to suppress epithelial-mesenchymal transition[J]. Theranostics, 2018, 8: 3707-3721.
[10]Park JM, Wu T, Cyr AR, et al. The role of Tcfap2c in tumorigenesis and cancer growth in an activated Neu model of mammary carcinogenesis[J]. Oncogene, 2015, 34: 6105-6114.
[11]Osella-abate S, Novelli M, Quaglino P, et al. Expression of AP-2 alpha, AP-2 gamma and ESDN in primary melanomas: correlation with histopathological features and potential prognostic value[J]. J Dermatol Sci, 2012, 68: 202-204.
[12]Gee JMW, Eloranta JJ, Ibbitt JC, et al. Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival[J]. J Pathol, 2009, 217: 32-41.
[13]Ma M, Guo D, Tan Z, et al. Fucosyltransferase 8 (FUT8) regulation and breast cancer suppression by transcription factor activator protein 2γ (AP-2γ)[J]. Cancer Sci, 2021, 112:3190-3204.
[14]刘逢秋, 管小琴, 王娅兰, 等.MIBG对人肝癌HepG2细胞增殖的影响[J]. 基础医学与临床, 2014, 34: 1221-1225.

[1]	ZHAO Yu-shan, JI Meng-die, DONG Yu-cheng, GUO Xin, SONG Bo-yuan, CHEN Yang. Epigenetic regulation mechanism of EZH2 gene in hepatocellular carcinoma [J]. Basic & Clinical Medicine, 2022, 42(6): 864-870.
[2]	HUANG Rong, ZHANG Jian, CHE Xu. Effect of SLC4A10 expression on prognosis of patient with hepatocellular carcinoma [J]. Basic & Clinical Medicine, 2022, 42(3): 461-466.
[3]	WANG Yu-min, CHEN Ji-chao, WANG Hong-quan, WANG Jin-hua, TANG Bo. Research progress of microRNAs as remodelers of lipid metabolic reprogramming in hepatocellular carcinoma [J]. Basic & Clinical Medicine, 2022, 42(12): 1930-1934.
[4]	WU Na, WANG Dong, LI Jing-min, BAI Xian-yong. Hydroxysafflor yellow A inhibits epithelial- mesenchymal transition in hepatocellular carcinoma cell line Huh7 [J]. Basic & Clinical Medicine, 2021, 41(10): 1423-1427.
[5]	WU Na, WANG Dong, BAI Xian-yong. Progress in research on autophagy and hepatocellular carcinoma [J]. Basic & Clinical Medicine, 2021, 41(10): 1514-1517.
[6]	TIAN Xiao-xing, QIN Li-pin, LI Qian. Regulation of invasion and migration of cell line Huh7 by lncRNA TINCR via miR-7 [J]. Basic & Clinical Medicine, 2020, 40(8): 1041-1046.
[7]	NI An-ni, LIANG Qing-yang, YAO Hong-fei, LI Gen-liang, TANG Yu-lian. Effect of arachidonic acid metabolism gene on cyclooxygenase P450 pathway in hepatocellular carcinoma of mice [J]. Basic & Clinical Medicine, 2020, 40(8): 1053-1058.
[8]	CAO Ming-yue, LI Gao-xiang, CHEN Yu-zhu, HUANG Wei, YANG Nan, LIU Yan-yong. Catecholamine stress hormones promote the cell cycle re-entry of G₀ phase in mouse hepatocarcinoma cell line H22 [J]. Basic & Clinical Medicine, 2020, 40(7): 897-902.
[9]	LIU Na-si, CAO Ming-yue, WU You-ming, HUANG Wei, YANG Nan, LIU Yan-yong. HSP90 inhibitor inhibits glycolysis and promotes apoptosis of mouse hepatocarcinoma cell line H22 [J]. Basic & Clinical Medicine, 2020, 40(7): 912-916.
[10]	ZHANG Xin-ran, ZHANG Yi, GAO Hui-er, QIANG Zhao-yan, LI Yong-mei. Shc3 over-expression inhibits apoptosis of HCC cells and is involved in drug resistance [J]. Basic & Clinical Medicine, 2020, 40(4): 473-478.
[11]	WANG Ding-ding, LIANG Jun-bo, WANG Xiao-yue. Effects of ARID1A loss on transcriptional regulation in hepatocellular carcinoma cell line PLC/PRF/5 [J]. Basic & Clinical Medicine, 2020, 40(4): 501-505.
[12]	LEI Qiao-li, RAO Qi-bin, LIN Ze-wen. Taurine combined with SN50 inhibits the proliferation of human hepatocellular carcinoma cell line HepG2 [J]. Basic & Clinical Medicine, 2020, 40(3): 340-345.
[13]	WU Da-ping, XU Lu, WU Huan-liang, ZHENG Wen-hong, ZHENG Xiao-mei, XIE Wen-rui. miR-150-5p enhances radiotherapy sensitivity of hepatocellular carcinoma cells line HepG2 through targeting SIRT1 [J]. Basic & Clinical Medicine, 2020, 40(3): 321-327.
[14]	HUANG Hai-liang, DING Wei-wei, LI Dong-xue. Over-expression of CRNDE promotes proliferation and migration in human hepatoma cell line HepG2 [J]. Basic & Clinical Medicine, 2020, 40(2): 219-223.
[15]	. Research progress in correlation between PTEN and new targeted drug resistance to hepatocellular carcinoma [J]. Basic & Clinical Medicine, 2019, 39(4): 581-584.